Stephen Schuster: Mosunetuzumab Leads to Durable Complete Remissions in Non-Hodgkin Lymphoma

Patients with both indolent and aggressive non-Hodgkin lymphomas responded to treatment with the monoclonal antibody, even those whose disease had not responded to CAR T-cell therapy. Stephen J. Schuster, MD, shares results from this phase I/Ib trial, which was presented as a plenary abstract.

SHARE